Ramelteon

貨號 Cat. No.
S1259
規格 Size
10mM/1mL~50mg
品牌 Brand
Selleckchem

Description


Ramelteon
Catalog No.S12591 Product Citations

Ramelteon is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.


















Size Price Stock Quantity  




























10mM/1mLIn DMSO USD 352 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
2mg USD 138 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
10mg USD 592 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
50mg USD 2104 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 




 Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw


Biological Activity







































Description Ramelteon is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.
Targets MT1 receptor MT2 receptor MT receptor (chicken)      
IC50 14 pM (Ki) 112 pM (Ki) 23.1 pM (Ki) [1]      
In vitro Ramelteon inhibits forskolin-stimulated cAMP production with IC50 of 21.2 pM in CHO cells. [1] Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively. Ramelteon inhibits Xenopus laevis melanophore pigment granule aggregation with pEC50 of 11.48. [2]Ramelteon (1 nM) increases ERK1/2 phosphorylation not only in MT1/MT2 cerebellar granule cells but also in cerebellar granule cells expressing only one of the two melatonin receptors. 4P-PDOT blocks the stimulatory action of Ramelteon (1 nM) in MT1 KO cerebellar granule cells, while luzindole attenuates the action of Ramelteon (1 nM) in MT2 KO cerebellar granule cells. Ramelteon (100 μM) induces any pigment dispersion while melatonin completely disperses aggregated melanophores at 10 μM. [3]
In vivo Ramelteon (10 mg/kg, i/p) significantly reduces NREM sleep latency in rat and also produces a short-lasting increase in nonrapid eye movement (NREM) sleep duration, but the NREM power spectrum is unaltered. [2]Ramelteon (0.1 mg/kg and 1 mg/kg, p.o.) accelerates reentrainment of running wheel activity rhythm to the new lightdark cycle in rats without affecting learning or memory. [4] Ramelteon (0.03 mg/kg and 0.3 mg/kg, p.o.) significantly shortens latency to sleep onset and significantly increases total duration of sleep in freely moving monkeys without affecting the general behavior of the monkeys. [5]
Features A tricyclic synthetic analog of melatonin.

Protocol(Only for Reference)


Kinase Assay: [1]









Binding assays Cells expressing the tested receptor are selected and cultured in Eagle’s Minimum Essential Medium-α (MEM-α) supplemented with 10% dialyzed fetal bovine serum (dFBS) under a 5% CO2/95% air atmosphere. Cells are harvested at confluence in Ca2+-Mg2+ free Hanks’ balanced salt solution containing 5 mM EDTA and collected by centrifugation. Cells are homogenized in ice-cold 50 mM Tris–HCl buffer (pH 7.7 at 25 ℃), washed twice, pelleted, and stored at −30 ℃ until the binding assays are conducted. Ramelteon and 40 pM 2-[125I]melatonin are mixed with the thawed homogenate in a total volume of 1 mL and incubated at 25 ℃ for 150 min. The reaction is terminated by addition of 3 mL of ice-cold buffer followed by vacuum filtration on a Whatman GF/B. The filter is washed twice and radioactivity is counted by a γ-counter. Nonspecific binding is defined as the binding in the presence of 10 μM melatonin.

Animal Study: [4]





















Animal Models estrogen-deficient ovariectomized (OVX) rats
Dosages 1 mg/kg
Administration Orally
Solubility 0.5% methylcellulose, 30 mg/mL

1


References


Clinical Trial Information( data from http://clinicaltrials.gov)





















































NCT Number Recruitment Conditions Sponsor

/Collaborators
Start Date Phases
NCT01677182 Recruiting Bipolar Disorder Takeda   Phase 3
NCT01685151 Withdrawn Bipolar Disorder Takeda   Phase 3
NCT01467713 Recruiting Bipolar Disorder Takeda   Phase 3
NCT01467700 Recruiting Acute Depressive Episode Takeda   Phase 3
NCT01207050 Recruiting Insomnia|Brain Injury Kessler Foundation   Phase 4

Chemical Information


Download Ramelteon SDF


 

















Molecular Weight (MW) 259.34
Formula

C16H21NO2


CAS No. 196597-26-9















Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms Rozerem, TAK-375

 


























Solubility (25°C) * In vitro DMSO 52 mg/mL (200 mM)
Water <1 mg/mL (<1 mM)
Ethanol 52 mg/mL (200 mM)
In vivo 0.5% methylcellulose, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.


 








Chemical Name (S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide

 

Preparing Stock Solutions



















Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.25934 2.5934 5.1868 7.7802


Product Citations (1)




 


 


 


 


 

詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢